>

Genmab Valuation

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>GMA</div>
GMAB -- Denmark Stock  

DKK 1,376  2.50  0.18%

What is the current enterprise value of Genmab AS? Genmab AS retains a regular Real Value of kr1177.58 per share. The prevalent price of the corporation is kr1376.5. At this time the corporation appears to be over valued. This module calculates the value of Genmab AS from evaluating the corporation fundamentals such as Return On Asset of 13.97 , Return On Equity of 19.64  and Current Valuation of 77.16 B as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.
View Valuation For
Refresh
Genmab AS Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Genmab AS's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Over Valued
Today
1,376
4th of April 2020
1,178
Real Value
1,514
Upside
Genmab AS is very steady asset. Calculation of real value of Genmab AS is based on 3 months time horizon. Increasing Genmab AS time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Genmab AS is rated # 3 in beta category among related companies. It is rated # 2 in price to sales category among related companies fabricating about  91.06  of Price to Sales per Beta.
Please check Risk vs Return Analysis. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page